Holen Sie sich die Stockscreener-App
7.87
0.25%
0.02
Schlusskurs vom Vortag:
$7.85
Offen:
$7.85
24-Stunden-Volumen:
860.01K
Relative Volume:
0.48
Marktkapitalisierung:
$544.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-4.981
EPS:
-1.58
Netto-Cashflow:
$-27.38M
1W Leistung:
+0.00%
1M Leistung:
+305.67%
6M Leistung:
+450.35%
1J Leistung:
+293.50%
1-Tages-Spanne:
$7.84
$7.88
1-Wochen-Bereich:
$7.82
$7.9001
52-Wochen-Spanne:
$0.8301
$8.20
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Firmenname
Regulus Therapeutics Inc
Sektor
Branche
Telefon
858-202-6300
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Vergleichen Sie RGLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
7.87 | 544.87M | 0 | -30.04M | -27.38M | -1.58 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-18 | Eingeleitet | Leerink Partners | Outperform |
| 2018-03-28 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-06 | Bestätigt | Wedbush | Outperform |
| 2017-01-30 | Herabstufung | Needham | Buy → Hold |
| 2017-01-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-11-02 | Bestätigt | Needham | Buy |
| 2016-07-25 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | FBR Capital | Outperform |
| 2016-06-28 | Bestätigt | Needham | Buy |
| 2016-06-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-04-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2015-04-21 | Fortgesetzt | FBR Capital | Outperform |
| 2014-11-24 | Eingeleitet | Deutsche Bank | Buy |
| 2014-08-07 | Bestätigt | FBR Capital | Outperform |
| 2013-08-14 | Bestätigt | Needham | Buy |
Alle ansehen
Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Regulus (RGLS) Sees Increased Put Trading Activity | RGLS Stock News - GuruFocus
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus
Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily
Novartis Gains Further Renal Territory With Regulus Acquisition - insights.citeline.com
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (RGLS) - Seeking Alpha
Regulus Therapeutics stock soars on acquisition deal with Novartis By Investing.com - Investing.com Nigeria
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target - marketscreener.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc.RGLS - PR Newswire
India’s Competition Commission Clears J&K Bank in Antitrust Case - PYMNTS.com
Top Midday Gainers - marketscreener.com
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull
Novartis to buy Regulus Therapeutics for up to $1.7 billion - MSN
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - Reuters
Novartis to Acquire Regulus Therapeutics in Potential $1.7B Deal - Contract Pharma
Generac, Regulus Therapeutics, Garmin - TradingView
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis By Stocktwits - Investing.com India
Regulus Therapeutics' stock price doubles on Novartis's buyout offer - TradingView
Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus
Latham & Watkins Advises Regulus Therapeutics in Acquisition by Novartis AG - Latham & Watkins LLP
Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regulus Therapeutics Inc-Aktie (RGLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BALTIMORE DAVID | Director |
Jan 30 '25 |
Buy |
1.06 |
19,610 |
20,787 |
22,169 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 13 '25 |
Sale |
1.26 |
38,547 |
48,693 |
54,634 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
49,546 |
| Hagan Joseph P | Chief Executive Officer |
Jan 13 '25 |
Sale |
1.26 |
115,290 |
145,634 |
222,572 |
| Hagan Joseph P | Chief Executive Officer |
Jan 14 '25 |
Sale |
1.26 |
11,764 |
14,860 |
210,808 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 13 '25 |
Sale |
1.26 |
38,716 |
48,906 |
50,566 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
45,478 |
| Klassen Preston | President & Head of R & D |
Jan 13 '25 |
Sale |
1.26 |
31,445 |
39,721 |
36,055 |
| Collier Kathryn J | Director |
Jul 25 '24 |
Buy |
1.82 |
4,000 |
7,280 |
6,740 |
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):